0001533743 2026-01-01 2026-06-30 0001533743 2026-08-07 0001533743 2026-06-30 0001533743 2025-12-31 0001533743 2026-04-01 2026-06-30 0001533743 2025-04-01 2025-06-30 0001533743 2025-01-01 2025-06-30 0001533743 us-gaap:CommonStockMember 2024-12-31 0001533743 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001533743 us-gaap:TreasuryStockCommonMember 2024-12-31 0001533743 us-gaap:RetainedEarningsMember 2024-12-31 0001533743 2024-12-31 0001533743 us-gaap:CommonStockMember 2025-03-31 0001533743 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001533743 us-gaap:TreasuryStockCommonMember 2025-03-31 0001533743 us-gaap:RetainedEarningsMember 2025-03-31 0001533743 2025-03-31 0001533743 us-gaap:CommonStockMember 2025-12-31 0001533743 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001533743 us-gaap:TreasuryStockCommonMember 2025-12-31 0001533743 us-gaap:RetainedEarningsMember 2025-12-31 0001533743 us-gaap:CommonStockMember 2026-03-31 0001533743 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001533743 us-gaap:TreasuryStockCommonMember 2026-03-31 0001533743 us-gaap:RetainedEarningsMember 2026-03-31 0001533743 2026-03-31 0001533743 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001533743 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001533743 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-03-31 0001533743 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001533743 2025-01-01 2025-03-31 0001533743 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001533743 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001533743 us-gaap:TreasuryStockCommonMember 2025-04-01 2025-06-30 0001533743 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001533743 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001533743 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001533743 us-gaap:TreasuryStockCommonMember 2026-01-01 2026-03-31 0001533743 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001533743 2026-01-01 2026-03-31 0001533743 us-gaap:CommonStockMember 2026-04-01 2026-06-30 0001533743 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0001533743 us-gaap:TreasuryStockCommonMember 2026-04-01 2026-06-30 0001533743 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0001533743 us-gaap:CommonStockMember 2025-06-30 0001533743 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001533743 us-gaap:TreasuryStockCommonMember 2025-06-30 0001533743 us-gaap:RetainedEarningsMember 2025-06-30 0001533743 2025-06-30 0001533743 us-gaap:CommonStockMember 2026-06-30 0001533743 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001533743 us-gaap:TreasuryStockCommonMember 2026-06-30 0001533743 us-gaap:RetainedEarningsMember 2026-06-30 0001533743 us-gaap:SubsequentEventMember 2026-07-30 2026-07-30 0001533743 PCSA:CHZTokensMember PCSA:SoldMember 2026-06-30 0001533743 2026-07-30 2026-07-30 0001533743 PCSA:EmployeeMember 2026-01-01 2026-01-01 0001533743 us-gaap:InvestorMember 2026-02-17 2026-02-17 0001533743 PCSA:DirectorsOfficersAndEmployeesMember 2026-01-01 2026-06-30 0001533743 PCSA:AtTheMarketAgreementMember 2026-04-01 2026-04-30 0001533743 PCSA:DirectorsMember us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-06-30 0001533743 2026-02-15 2026-02-15 0001533743 PCSA:TwoThousandAndNineteenPlanMember 2019-06-19 0001533743 PCSA:TwoThousandAndNineteenPlanMember 2026-06-30 0001533743 us-gaap:EmployeeStockOptionMember 2026-06-30 0001533743 us-gaap:EmployeeStockOptionMember 2025-06-30 0001533743 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-06-30 0001533743 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-06-30 0001533743 us-gaap:RestrictedStockUnitsRSUMember 2026-06-30 0001533743 us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-06-30 0001533743 PCSA:EmployeesAndDirectorsMember us-gaap:RestrictedStockUnitsRSUMember us-gaap:SubsequentEventMember 2026-07-26 2026-07-26 0001533743 PCSA:StockPurchaseWarrantsMember 2026-01-01 2026-06-30 0001533743 PCSA:StockPurchaseWarrantsMember 2026-06-30 0001533743 PCSA:ResearchAndDevelopmentMember 2026-04-01 2026-06-30 0001533743 PCSA:ResearchAndDevelopmentMember 2025-04-01 2025-06-30 0001533743 PCSA:ResearchAndDevelopmentMember 2026-01-01 2026-06-30 0001533743 PCSA:ResearchAndDevelopmentMember 2025-01-01 2025-06-30 0001533743 PCSA:GeneralAndAdministrativeMember 2026-04-01 2026-06-30 0001533743 PCSA:GeneralAndAdministrativeMember 2025-04-01 2025-06-30 0001533743 PCSA:GeneralAndAdministrativeMember 2026-01-01 2026-06-30 0001533743 PCSA:GeneralAndAdministrativeMember 2025-01-01 2025-06-30 0001533743 us-gaap:RestrictedStockUnitsRSUMember 2025-12-31 0001533743 us-gaap:CommonStockMember 2026-01-01 2026-06-30 0001533743 us-gaap:CommonStockMember 2025-01-01 2025-06-30 0001533743 us-gaap:RestrictedStockUnitsRSUMember 2026-04-01 2026-06-30 0001533743 us-gaap:RestrictedStockUnitsRSUMember 2025-04-01 2025-06-30 0001533743 us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-06-30 0001533743 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-06-30 0001533743 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-06-30 0001533743 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-06-30 0001533743 us-gaap:WarrantMember 2026-01-01 2026-06-30 0001533743 us-gaap:WarrantMember 2025-01-01 2025-06-30 0001533743 PCSA:CHZDigitalAssetsMember 2026-06-30 0001533743 PCSA:CHZTokensMember PCSA:PurchasedMember 2026-06-30 0001533743 PCSA:CorLystLLCMember 2026-04-01 2026-06-30 0001533743 PCSA:CorLystLLCMember 2025-04-01 2025-06-30 0001533743 PCSA:CorLystLLCMember 2026-01-01 2026-06-30 0001533743 PCSA:CorLystLLCMember 2025-01-01 2025-06-30 0001533743 PCSA:CorLystLLCMember 2025-06-30 0001533743 PCSA:CorLystLLCMember 2026-06-30 0001533743 PCSA:ChilizGroupMember 2026-01-01 2026-06-30 0001533743 PCSA:ChilizGroupMember 2026-06-30 0001533743 us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember 2026-04-01 2026-06-30 0001533743 us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember 2025-04-01 2025-06-30 0001533743 us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember 2026-01-01 2026-06-30 0001533743 us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember 2025-01-01 2025-06-30 0001533743 PCSA:ResearchAndDevelopmentPersonnelCostsMember 2026-04-01 2026-06-30 0001533743 PCSA:ResearchAndDevelopmentPersonnelCostsMember 2025-04-01 2025-06-30 0001533743 PCSA:ResearchAndDevelopmentPersonnelCostsMember 2026-01-01 2026-06-30 0001533743 PCSA:ResearchAndDevelopmentPersonnelCostsMember 2025-01-01 2025-06-30 0001533743 PCSA:GeneralAndAdministrativePersonnelCostsMember 2026-04-01 2026-06-30 0001533743 PCSA:GeneralAndAdministrativePersonnelCostsMember 2025-04-01 2025-06-30 0001533743 PCSA:GeneralAndAdministrativePersonnelCostsMember 2026-01-01 2026-06-30 0001533743 PCSA:GeneralAndAdministrativePersonnelCostsMember 2025-01-01 2025-06-30 0001533743 srt:MaximumMember PCSA:ContractResearchOrganizationMember PCSA:AgreementMember 2026-06-30 0001533743 PCSA:VidyaTherapeuticsIncMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember PCSA:MergerAgreementMember 2026-07-28 2026-07-28 0001533743 PCSA:VidyaTherapeuticsIncMember us-gaap:SeriesAPreferredStockMember us-gaap:SubsequentEventMember 2026-07-28 2026-07-28 0001533743 PCSA:VidyaTherapeuticsIncMember us-gaap:SeriesAPreferredStockMember us-gaap:SubsequentEventMember PCSA:MergerAgreementMember 2026-07-28 2026-07-28 0001533743 us-gaap:SubsequentEventMember PCSA:SecuritiesPurchaseAgreementMember 2026-07-30 2026-07-30 0001533743 us-gaap:SeriesAPreferredStockMember us-gaap:SubsequentEventMember PCSA:SecuritiesPurchaseAgreementMember 2026-07-30 2026-07-30 0001533743 us-gaap:SeriesAPreferredStockMember us-gaap:SubsequentEventMember PCSA:SecuritiesPurchaseAgreementMember 2026-07-30 0001533743 us-gaap:SeriesAPreferredStockMember us-gaap:SubsequentEventMember 2026-07-28 2026-07-28 0001533743 us-gaap:SubsequentEventMember 2026-07-23 2026-07-23 iso4217:USD shares iso4217:USD shares pure PCSA:Segment PCSA:Chiliz false Q2 --12-31 0001533743

10-Q true 2026-06-30 2026 false 001-39531 Processa Pharmaceuticals, Inc. DE 45-1539785 601 21st Street Suite 300 Vero Beach FL 32960 (772) 453-2899 Common Stock, $0.0001 par value per share PCSA NASDAQ Yes Yes Non-accelerated Filer true false false 2793386

196325

5536955

1398024

133919

472003

2066352

5670874

1145180

993701

3210

3812

2069562

7813567

1659438

1056796

727465

1179457

2386903

2236253

2386903

2236253

0.0001

1000000

0.0001

1000000000

2793386

2572114

2571914

279

257

107108086

106660090

300000

-107425706

-100783033

-317341

5577314

2069562

7813567

649877

2447286

2459041

4035767

1686261

1503497

3208311

2762006

-2336138

-3950783

-5667352

-6797773

768348

828172

159005

8003

8006

-2003

8862

11856

21444

-929356

16865

-975321

29450

-3265494

-3933918

-6642673

-6768323

-1.19

-6.26

-2.47

-13.48

2750742

628796

2687295

502085

148308

89215355

-200

-300000

-87219199

1696171

473

227710

227711

62267

4438564

4438570

1438

1439

-2834405

210976

93880191

-200

-300000

-90053604

3526608

5741

203250

203251

1395760

140

6320092

6320232

887

8965

-3933918

1611590

162

100394568

-200

-300000

-93987522

6107208

2572114

257

106660090

-200

-300000

-100783033

5577314

1281

95962

95963

86956

199991

200000

17796

45101

45103

112

320

200

-300000

-200

300000

-3377179

2677835

269

106700824

-104160212

2540881

2677835

269

106700824

-104160212

2540881

812

92105

64409

162218

162223

64409

162218

162223

50330

152939

152944

-3265494

2793386

279

107108086

-107425706

-317341

2793386

279

107108086

-107425706

-317341

-6642673

-6768323

602

46359

828172

159005

188068

430962

270404

-745834

-45073

602642

-95126

-451992

684512

-5586580

-5000253

500000

186000

-314000

560270

10758802

320

10404

2850

559950

10745548

-5340630

5745295

5536955

1191325

196325

6936620

10325

1880

Note 1 – Organization and Summary of Significant Accounting Policies Organization On July 28, 2026, Processa Pharmaceuticals, Inc. (the “Company,” “we,” “us,” and “our”) acquired Vidya Therapeutics, Inc. (“Vidya”) pursuant to the terms of an Agreement and Plan of Merger, dated as of July 28, 2026 (such agreement, the “Merger Agreement” and the transaction consummated via Merger Agreement, the “Vidya Acquisition”) by and among our company, Venus Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Company, Venus Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company, and Vidya (see Note 9). The accompanying unaudited condensed financial statements do not give effect to our acquisition of Vidya. The Vidya Acquisition brought into our pipeline Vidya’s lead asset, VT-7208, an orally available, covalently binding, irreversible, CNS-penetrant Bruton’s tyrosine kinase inhibitor (“BTKi”) rationally designed to optimize for selectivity, potency, and tolerability. In connection with the Vidya Acquisition, we received $<span id="xdx_903_ecustom--GrossProceedsFromIssuanceOfPrivatePlacement_pn6n6_c20260730__20260730__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z63uwL3Gheuj" title="Gross proceeds from issuance of private placement">200 million in gross proceeds from a private placement financing of shares of our non-voting convertible preferred stock. We intend to use the net proceeds of $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn5n6_c20260730__20260730__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z3AP4GNIVUPh" title="Proceeds from issuance of private placement">183.3 million from the private placement to fund operations into the second half of 2029 and through key clinical milestones, including top-line data from Phase 2 proof-of-concept studies for food allergy, chronic spontaneous urticaria (“CSU”), and relapsing multiple sclerosis (“RMS”). Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions of the Securities and Exchange Commission (“SEC”) on Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all the information and disclosures required by U.S. GAAP for complete financial statements. All material intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our financial position and of the results of operations and cash flows for the periods presented. These condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC. The results of operations for the interim periods shown in this report are not necessarily indicative of the results that may be expected for any other interim period or for the full year. Liquidity As of June 30, 2026 our net assets were not sufficient to fund our future operations. However, on July 30, 2026 we closed a private placement, as described in Note 9, for gross proceeds of $<span id="xdx_908_ecustom--GrossProceedsFromIssuanceOfPrivatePlacement_pn6n6_c20260730__20260730__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zlXADZRuNZAk" title="Gross proceeds from issuance of private placement">200 million from which we received net proceeds of $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn5n6_c20260730__20260730__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zIZVT7SuQwCf" title="Net proceeds from issuance of private placement">183.3 million. Management believes that with these funds our liquid assets are sufficient to meet obligations for at least one year from the issuance date of these financial statements. Use of Estimates In preparing our condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP and pursuant to the rules and regulations of the SEC, we make estimates and judgments that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Estimates are used for, but not limited to preclinical and clinical trial expenses, stock-based compensation, intangible assets, future milestone payments and income taxes. These estimates and assumptions are continuously evaluated and are based on management’s experience and knowledge of the relevant facts and circumstances. While we believe the estimates to be reasonable, actual results could differ materially from those estimates and could impact future results of operations and cash flows. Digital Assets Our digital assets consist of Chiliz (CHZ) tokens and we have accounted for it in accordance with ASC 350-60, Intangibles – Goodwill and Other – Crypto Assets (“ASC 350-60”). We initially recorded the digital assets at cost and have subsequently remeasured at fair value as of the balance sheet date with changes in fair value recognized as unrealized gain or losses in the condensed consolidated statement of operations. During the six months ended June 30, 2026, we sold 11,000,000 CHZ coins for $186,000 and recognized a realized loss of $159,005 related to the sale. We will continue to recognize any realized gains or losses in the consolidated statement of operations based on the fair value of the digital assets on the date of sale or derecognition. Income Taxes We account for income taxes in accordance with ASC Topic 740, Income Taxes. Deferred income taxes are recorded for the expected tax consequences of temporary differences between the basis of assets and liabilities for financial reporting purposes and amounts recognized for income tax purposes. At June 30, 2026 and December 31, 2025, we recorded a valuation allowance equal to the full recorded amount of our net deferred tax assets since it is more-likely-than-not that such benefits will not be realized. The valuation allowance is reviewed quarterly and is maintained until sufficient positive evidence exists to support its reversal. Under ASC 740-270 Income Taxes – Interim Reporting, we are required to project our annual federal and state effective income tax rate and apply it to the year-to-date ordinary operating tax basis loss before income taxes. Based on the projection, no current income tax benefit or expense is expected for 2026 and the foreseeable future since we expect to generate taxable net operating losses. Concentration of Credit Risk Financial instruments that potentially subject us to significant concentration of credit risk consist primarily of our cash and cash equivalents. We utilize only well-established banks and financial institutions with high credit ratings. Balances on deposit are insured by the Federal Deposit Insurance Corporation (FDIC) up to specified limits. While total cash held by our banks at June 30, 2026 did not exceed FDIC limits, recent private placement net proceeds of $183.3 million (see Note 9) have caused cash balances to exceed FDIC limits. Recent Accounting Pronouncements From time to time, the Financial Accounting Standards Board (“FASB”) or other standard setting bodies issue new accounting pronouncements. Updates to the FASB Accounting Standards Codification are communicated through issuance of an Accounting Standards Update (“ASU”). We have implemented all new accounting pronouncements that are in effect and that may impact our condensed consolidated financial statements. We have evaluated recently issued accounting pronouncements and determined that there is no material impact on our condensed consolidated financial position or results of operations.

Organization On July 28, 2026, Processa Pharmaceuticals, Inc. (the “Company,” “we,” “us,” and “our”) acquired Vidya Therapeutics, Inc. (“Vidya”) pursuant to the terms of an Agreement and Plan of Merger, dated as of July 28, 2026 (such agreement, the “Merger Agreement” and the transaction consummated via Merger Agreement, the “Vidya Acquisition”) by and among our company, Venus Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Company, Venus Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company, and Vidya (see Note 9). The accompanying unaudited condensed financial statements do not give effect to our acquisition of Vidya. The Vidya Acquisition brought into our pipeline Vidya’s lead asset, VT-7208, an orally available, covalently binding, irreversible, CNS-penetrant Bruton’s tyrosine kinase inhibitor (“BTKi”) rationally designed to optimize for selectivity, potency, and tolerability. In connection with the Vidya Acquisition, we received $<span id="xdx_903_ecustom--GrossProceedsFromIssuanceOfPrivatePlacement_pn6n6_c20260730__20260730__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z63uwL3Gheuj" title="Gross proceeds from issuance of private placement">200 million in gross proceeds from a private placement financing of shares of our non-voting convertible preferred stock. We intend to use the net proceeds of $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn5n6_c20260730__20260730__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z3AP4GNIVUPh" title="Proceeds from issuance of private placement">183.3 million from the private placement to fund operations into the second half of 2029 and through key clinical milestones, including top-line data from Phase 2 proof-of-concept studies for food allergy, chronic spontaneous urticaria (“CSU”), and relapsing multiple sclerosis (“RMS”). 200000000

183300000

Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions of the Securities and Exchange Commission (“SEC”) on Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all the information and disclosures required by U.S. GAAP for complete financial statements. All material intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our financial position and of the results of operations and cash flows for the periods presented. These condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC. The results of operations for the interim periods shown in this report are not necessarily indicative of the results that may be expected for any other interim period or for the full year.

Liquidity As of June 30, 2026 our net assets were not sufficient to fund our future operations. However, on July 30, 2026 we closed a private placement, as described in Note 9, for gross proceeds of $<span id="xdx_908_ecustom--GrossProceedsFromIssuanceOfPrivatePlacement_pn6n6_c20260730__20260730__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zlXADZRuNZAk" title="Gross proceeds from issuance of private placement">200 million from which we received net proceeds of $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn5n6_c20260730__20260730__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zIZVT7SuQwCf" title="Net proceeds from issuance of private placement">183.3 million. Management believes that with these funds our liquid assets are sufficient to meet obligations for at least one year from the issuance date of these financial statements. 200000000

183300000

Use of Estimates In preparing our condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP and pursuant to the rules and regulations of the SEC, we make estimates and judgments that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Estimates are used for, but not limited to preclinical and clinical trial expenses, stock-based compensation, intangible assets, future milestone payments and income taxes. These estimates and assumptions are continuously evaluated and are based on management’s experience and knowledge of the relevant facts and circumstances. While we believe the estimates to be reasonable, actual results could differ materially from those estimates and could impact future results of operations and cash flows.

Digital Assets Our digital assets consist of Chiliz (CHZ) tokens and we have accounted for it in accordance with ASC 350-60, Intangibles – Goodwill and Other – Crypto Assets (“ASC 350-60”). We initially recorded the digital assets at cost and have subsequently remeasured at fair value as of the balance sheet date with changes in fair value recognized as unrealized gain or losses in the condensed consolidated statement of operations. During the six months ended June 30, 2026, we sold 11,000,000 CHZ coins for $186,000 and recognized a realized loss of $159,005 related to the sale. We will continue to recognize any realized gains or losses in the consolidated statement of operations based on the fair value of the digital assets on the date of sale or derecognition.

11000000

186000

159005

Income Taxes We account for income taxes in accordance with ASC Topic 740, Income Taxes. Deferred income taxes are recorded for the expected tax consequences of temporary differences between the basis of assets and liabilities for financial reporting purposes and amounts recognized for income tax purposes. At June 30, 2026 and December 31, 2025, we recorded a valuation allowance equal to the full recorded amount of our net deferred tax assets since it is more-likely-than-not that such benefits will not be realized. The valuation allowance is reviewed quarterly and is maintained until sufficient positive evidence exists to support its reversal. Under ASC 740-270 Income Taxes – Interim Reporting, we are required to project our annual federal and state effective income tax rate and apply it to the year-to-date ordinary operating tax basis loss before income taxes. Based on the projection, no current income tax benefit or expense is expected for 2026 and the foreseeable future since we expect to generate taxable net operating losses.

Concentration of Credit Risk Financial instruments that potentially subject us to significant concentration of credit risk consist primarily of our cash and cash equivalents. We utilize only well-established banks and financial institutions with high credit ratings. Balances on deposit are insured by the Federal Deposit Insurance Corporation (FDIC) up to specified limits. While total cash held by our banks at June 30, 2026 did not exceed FDIC limits, recent private placement net proceeds of $183.3 million (see Note 9) have caused cash balances to exceed FDIC limits.

183300000

Recent Accounting Pronouncements From time to time, the Financial Accounting Standards Board (“FASB”) or other standard setting bodies issue new accounting pronouncements. Updates to the FASB Accounting Standards Codification are communicated through issuance of an Accounting Standards Update (“ASU”). We have implemented all new accounting pronouncements that are in effect and that may impact our condensed consolidated financial statements. We have evaluated recently issued accounting pronouncements and determined that there is no material impact on our condensed consolidated financial position or results of operations.

Note 2 – Stockholders’ Equity Common Stock During the six months ended June 30, 2026, we issued the following shares of common stock: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On January 1, 2026, we issued 1,169 shares of common stock to certain employees, net of 112 shares of common stock withheld for income and FICA taxes owed upon the distribution of the shares;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On February 17, 2026, we sold 86,956 shares of our common stock to an accredited investor in a private placement transaction for $200,000;</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">We sold 82,205 shares of common stock to certain directors, officers, and employees for approximately $207,000 during the six months ended June 30, 2026;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif">In April 2026, we sold 50,330 shares of common stock under our ATM Offering for approximately $153,000 in net proceeds; and </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On June 26, 2026, we issued <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsMember_zlV9hYxZchqh" title="Shares issued">812 shares of common stock to our directors for restricted stock units that reached the distribution requirement.</td></tr> </table> Treasury Stock On February 15, 2026, the Board of Directors (the “Board”) approved the retirement of the 200 shares held in treasury stock.

1169

112

86956

200000

82205

207000

50330

153000

812

200

<p id="xdx_803_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zCRZj04kPRee" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 11pt; text-align: justify; text-indent: -11pt">Note 3 - Stock-based Compensation On June 19, 2019, our stockholders approved, and we adopted, the Processa Pharmaceuticals Inc. 2019 Omnibus Equity Incentive Plan (the “2019 Plan”). The 2019 Plan allows us, under the direction of our Board or a committee thereof, to make grants of stock options, restricted and unrestricted stock and other stock-based awards to employees, including our executive officers, consultants and directors. The 2019 Plan provides for the aggregate issuance of <span id="xdx_900_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20190619__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenPlanMember_zMhQtrBA7TH7" title="Maximum equity available for issuance under the plan">432,000 shares of our common stock. At June 30, 2026, we had <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20260630__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenPlanMember_zddoNLoCsHlc" title="Shares available for future grants">232,721 shares available for future grants, which were all granted to employees and directors on July 26, 2026. Stock Compensation Expense <p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zYiV4JxzEVAe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">We recorded stock-based compensation expense for the three and six months ended June 30, 2026 and 2025 as follows: Schedule of Stock-Based Compensation Expense <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20260401__20260630_zpRbVY3gorSj" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20250401__20250630_z8eVkXrF2K16" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20260101__20260630_zhFHj94IFM79" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20250101__20250630_z9n3vSjP0uo3" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_400_eus-gaap--AllocatedShareBasedCompensationExpense_hcustom--IncomeLocationBalanceAxis__custom--ResearchAndDevelopmentMember_znEdckZ1y0la" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Research and development</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">17,145</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">8,613</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">34,289</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">55,333</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_hcustom--IncomeLocationBalanceAxis__custom--GeneralAndAdministrativeMember_zrACpr5CQuaj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">74,960</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">194,638</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">153,779</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">375,629</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_zPtG6TnOzblb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">92,105</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">203,251</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">188,068</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">430,962</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Stock Options <p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTPh2tYZ7Vkg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">The following table summarizes our stock option activity during the six months ended June 30, 2026: Schedule of Stock Option Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total options Outstanding</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted average exercise price</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted average remaining contractual life (in years)</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Outstanding as of January 1, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20260101__20260630_zYcDwodPcGRk" style="width: 14%; text-align: right" title="Options outstanding, beginning balance">136,372</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20260101__20260630_zRiOkh5HUGUk" style="width: 14%; text-align: right" title="Weighted average exercise price, beginning balance">13.43</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Options granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20260101__20260630_z2RtqVq5iZOb" style="text-align: right" title="Options, granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20260101__20260630_zWGHfTdnU2sg" style="text-align: right" title="Weighted average exercise price, granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Forfeited or expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20260101__20260630_zNzWSgSCsZCb" style="border-bottom: Black 1pt solid; text-align: right" title="Options, forfeited or expired">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20260101__20260630_zMddtwXkzpgl" style="border-bottom: Black 1pt solid; text-align: right" title="Forfeited or expired, granted">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Outstanding as of June 30, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20260101__20260630_zMXzO2Ey77gk" style="text-align: right" title="Options outstanding, ending balance">136,372</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20260101__20260630_z3NQDLb8Bq13" style="text-align: right" title="Weighted average exercise price, ending balance">13.43</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630_zdhjBAAYWLQc" title="Weighted average remaining contractual term, outstanding">9.2</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercisable as of June 30, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20260101__20260630_zbp5mQo3EU48" style="text-align: right" title="Options exercisable, ending balance">712</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20260101__20260630_zDiPsThJl2Sl" style="text-align: right" title="Weighted average exercise price, exercisable">1,615.67</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260630_z9XqHqWQrUcj" title="Weighted average remaining contractual term, exercisable">1.0</td><td style="text-align: left"> </td></tr> </table> No forfeiture rate was applied to these stock options. The aggregate intrinsic value of outstanding options was $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_do_c20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlzPNC4yHNM8" title="Aggregate intrinsic value of outstanding options"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_do_c20250630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjLvtvreDXn6" title="Aggregate intrinsic value of outstanding options">0 at both June 30, 2026 and 2025. No stock options were exercised during the six months ended June 30, 2026 or 2025. At June 30, 2026, unrecognized stock-based compensation expense for stock options of $<span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zQuNkMWu9d3j" title="Unrecognized share based compensation expense">514,000 is expected to be fully recognized over a weighted average period of <span id="xdx_906_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z37gTXRtiR0j" title="Weighted average period for recognition">2.3 years. Restricted Stock Units <p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zUt6J3aTbqce" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Activity with respect to our Restricted Stock Units (“RSUs”) during the six months ended June 30, 2026 was as follows: Schedule of Restricted Stock Units (“RSUs”) Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of shares</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted- average grant-date fair value per share</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Outstanding at January 1, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iS_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zKdU6NfNrFaf" style="width: 16%; text-align: right" title="Number of shares, Beginning balance">56,641</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zvQPInpQHprd" style="width: 16%; text-align: right" title="Weighted-average grant-date fair value per share, Beginning balance">31.02</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8DxXlJbMMHd" style="text-align: right" title="Number of shares, granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zh7DAJrJZpil" style="text-align: right" title="Weighted-average grant-date fair value per share, granted">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zOmGeytuguUe" style="text-align: right" title="Number of shares, forfeited">(312</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zBl5KkpJmPff" style="text-align: right" title="Weighted-average grant-date fair value per share, forfeited">201.72</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Distributed</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsDistributedInPeriod_iN_di_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zi1QpGYIZqk" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, distributed">(1,981</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsDistributedWeightedAverageGrantDateFairValue_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zcoLPKrIPKEf" style="text-align: right" title="Weighted-average grant-date fair value per share, distributed">429.70</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding at June 30, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iE_pid_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z28CSbtofF75" style="text-align: right" title="Number of shares, ending balance">54,348</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iE_pid_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zgfgP52Wcemb" style="text-align: right" title="Weighted-average grant-date fair value per share, ending balance">15.52</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Vested and unissued</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zef5QkQVEfz3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, vested and unissued">(8,738</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzVGpshsJNN4" style="text-align: right" title="Weighted-average grant-date fair value per share, vested and unissued">67.73</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Unvested at June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zE6sMLuYwsG7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, unvested">45,610</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zBFhFJwNO5df" style="text-align: right" title="Weighted-average grant-date fair value per share, unvested">5.51</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> At June 30, 2026, unrecognized stock-based compensation expense of approximately $<span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAa0YH5kS7yh" title="Unrecognized share based compensation expense">182,000 for RSUs is expected to be fully recognized over a weighted average period of <span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z5F1xYihJc62" title="Weighted average period for recognition">2.3 years. The unrecognized expense excludes approximately $<span id="xdx_908_ecustom--ExcludedUnrecognizedShareBasedCompensationExpense_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbibM0UMr1Kg" title="Excluded unrecognized share based compensation expense">12,000 of expense related to certain grants of RSUs with performance milestones that are not probable of occurring at this time. On July 26, 2026, we granted RSUs that represent <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20260726__20260726__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zVTyJFoj4pk7" title="Shares granted">232,721 shares of common stock to our employees and directors with a grant date fair value of $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20260726__20260726__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_z7xu2tkCsGxb" title="Fair value of granted price per shares">2.60. The RSUs vested immediately and the shares of common stock will be distributed within six months of the grant date. Holders of our vested RSUs will be issued shares of our common stock upon meeting the distribution restrictions contained in their Restricted Stock Unit Award Agreement. The distribution restrictions are different (longer) than the vesting schedule, imposing an additional restriction on the holder. While certain employees may hold fully vested RSUs, the individual does not hold any shares or have any rights of a stockholder until the distribution restrictions are met. Upon distribution to the employee, each RSU converts into one share of our common stock. The RSUs contain dividend equivalent rights. Warrants During the six months ended June 30, 2026, <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_do_c20260101__20260630__us-gaap--AwardTypeAxis__custom--StockPurchaseWarrantsMember_z34eDCXNC4H8" title="Warrants, expired">6,324 warrants expired and we did not grant any warrants and no warrants were exercised. We did not have any unrecognized stock-based compensation expense related to the <span id="xdx_90A_ecustom--ClassOfWarrantOrRightNumberOfSecuritiesOutstanding_iI_c20260630__us-gaap--AwardTypeAxis__custom--StockPurchaseWarrantsMember_zVa9EEHUBVp8" title="Warrants to purchase shares, outstanding">1,430,807 outstanding stock purchase warrants at June 30, 2026. The outstanding stock purchase warrants have a weighted average exercise price of $<span id="xdx_906_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_c20260101__20260630__us-gaap--AwardTypeAxis__custom--StockPurchaseWarrantsMember_znQjqPJDbGL1" title="Warrants exercise prices">14.53 and <span id="xdx_902_ecustom--WarrantsAndRightsOutstandingMaturityDateDescription_do_c20260101__20260630__us-gaap--AwardTypeAxis__custom--StockPurchaseWarrantsMember_zPcQx5j0cCJk" title="Warrants expiration, description">expire between January 18, 2027 and July 18, 2030.

432000

232721

<p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zYiV4JxzEVAe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">We recorded stock-based compensation expense for the three and six months ended June 30, 2026 and 2025 as follows: Schedule of Stock-Based Compensation Expense <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20260401__20260630_zpRbVY3gorSj" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20250401__20250630_z8eVkXrF2K16" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20260101__20260630_zhFHj94IFM79" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20250101__20250630_z9n3vSjP0uo3" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_400_eus-gaap--AllocatedShareBasedCompensationExpense_hcustom--IncomeLocationBalanceAxis__custom--ResearchAndDevelopmentMember_znEdckZ1y0la" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Research and development</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">17,145</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">8,613</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">34,289</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">55,333</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_hcustom--IncomeLocationBalanceAxis__custom--GeneralAndAdministrativeMember_zrACpr5CQuaj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">74,960</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">194,638</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">153,779</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">375,629</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_zPtG6TnOzblb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">92,105</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">203,251</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">188,068</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">430,962</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

17145

8613

34289

55333

74960

194638

153779

375629

92105

203251

188068

430962

<p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTPh2tYZ7Vkg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">The following table summarizes our stock option activity during the six months ended June 30, 2026: Schedule of Stock Option Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total options Outstanding</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted average exercise price</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted average remaining contractual life (in years)</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Outstanding as of January 1, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20260101__20260630_zYcDwodPcGRk" style="width: 14%; text-align: right" title="Options outstanding, beginning balance">136,372</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20260101__20260630_zRiOkh5HUGUk" style="width: 14%; text-align: right" title="Weighted average exercise price, beginning balance">13.43</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Options granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20260101__20260630_z2RtqVq5iZOb" style="text-align: right" title="Options, granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20260101__20260630_zWGHfTdnU2sg" style="text-align: right" title="Weighted average exercise price, granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Forfeited or expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20260101__20260630_zNzWSgSCsZCb" style="border-bottom: Black 1pt solid; text-align: right" title="Options, forfeited or expired">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20260101__20260630_zMddtwXkzpgl" style="border-bottom: Black 1pt solid; text-align: right" title="Forfeited or expired, granted">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Outstanding as of June 30, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20260101__20260630_zMXzO2Ey77gk" style="text-align: right" title="Options outstanding, ending balance">136,372</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20260101__20260630_z3NQDLb8Bq13" style="text-align: right" title="Weighted average exercise price, ending balance">13.43</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630_zdhjBAAYWLQc" title="Weighted average remaining contractual term, outstanding">9.2</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercisable as of June 30, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20260101__20260630_zbp5mQo3EU48" style="text-align: right" title="Options exercisable, ending balance">712</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20260101__20260630_zDiPsThJl2Sl" style="text-align: right" title="Weighted average exercise price, exercisable">1,615.67</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260630_z9XqHqWQrUcj" title="Weighted average remaining contractual term, exercisable">1.0</td><td style="text-align: left"> </td></tr> </table>

136372

13.43

136372

13.43

P9Y2M12D

712

1615.67

P1Y

514000

P2Y3M18D

<p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zUt6J3aTbqce" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Activity with respect to our Restricted Stock Units (“RSUs”) during the six months ended June 30, 2026 was as follows: Schedule of Restricted Stock Units (“RSUs”) Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of shares</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted- average grant-date fair value per share</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Outstanding at January 1, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iS_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zKdU6NfNrFaf" style="width: 16%; text-align: right" title="Number of shares, Beginning balance">56,641</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zvQPInpQHprd" style="width: 16%; text-align: right" title="Weighted-average grant-date fair value per share, Beginning balance">31.02</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8DxXlJbMMHd" style="text-align: right" title="Number of shares, granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zh7DAJrJZpil" style="text-align: right" title="Weighted-average grant-date fair value per share, granted">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zOmGeytuguUe" style="text-align: right" title="Number of shares, forfeited">(312</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zBl5KkpJmPff" style="text-align: right" title="Weighted-average grant-date fair value per share, forfeited">201.72</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Distributed</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsDistributedInPeriod_iN_di_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zi1QpGYIZqk" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, distributed">(1,981</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsDistributedWeightedAverageGrantDateFairValue_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zcoLPKrIPKEf" style="text-align: right" title="Weighted-average grant-date fair value per share, distributed">429.70</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding at June 30, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iE_pid_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z28CSbtofF75" style="text-align: right" title="Number of shares, ending balance">54,348</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iE_pid_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zgfgP52Wcemb" style="text-align: right" title="Weighted-average grant-date fair value per share, ending balance">15.52</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Vested and unissued</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zef5QkQVEfz3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, vested and unissued">(8,738</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzVGpshsJNN4" style="text-align: right" title="Weighted-average grant-date fair value per share, vested and unissued">67.73</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Unvested at June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zE6sMLuYwsG7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, unvested">45,610</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zBFhFJwNO5df" style="text-align: right" title="Weighted-average grant-date fair value per share, unvested">5.51</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

56641 31.02

312

201.72

1981 429.70 54348 15.52 -8738 67.73

45610

5.51

182000

P2Y3M18D

12000

232721

2.60

6324

1430807 14.53 expire between January 18, 2027 and July 18, 2030

Note 4 – Net Loss per Share of Common Stock Net Loss Per Share Basic net loss per share is computed by dividing our net loss available to common stockholders by the weighted average number of shares of common stock outstanding (which includes vested RSUs) during the period. Diluted loss per share is computed by dividing our net loss available to common stockholders by the diluted weighted average number of shares of common stock (which includes the potentially dilutive effect of stock options, unvested RSUs and warrants) during the period. Since we experienced a net loss for both periods presented, basic and diluted net loss per share is the same. As such, diluted loss per share for the six months ended June 30, 2026 and 2025 excludes the impact of potentially dilutive common shares since those shares would have an anti-dilutive effect on net loss per share. <p id="xdx_89B_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z9x0DbXY5MIb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">The computation of net loss per share for the three and six months ended June 30, 2026 and 2025 was as follows: Schedule of Net Loss Per Share Basic and Diluted <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20260401__20260630_zCtfPyviL7Yd" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20250401__20250630_zmKrGmDlX35d" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20260101__20260630_z1DOP83HvzU" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20250101__20250630_zLB9reV9pvqd" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Basic and diluted net loss per share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zGD1LQZ7vyo5" style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left">Net loss available to common stockholders</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(3,265,494</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(3,933,918</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(6,642,673</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(6,768,323</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Weighted average number of common shares-basic and diluted</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,750,742</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">628,796</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,687,295</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">502,085</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Basic and diluted net loss per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1.19</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(6.26</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2.47</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(13.48</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Weighted-average number of common shares outstanding – basic and diluted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcBuOZbcDn5f" title="Weighted average number of common shares outstanding - basic"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5KsmPJJxy47" title="Weighted average number of common shares outstanding - diluted">2,740,070</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250401__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4dPks3IyWI6" title="Weighted average number of common shares outstanding - basic"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250401__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zN1bxfyZFd0h" title="Weighted average number of common shares outstanding - diluted">621,815</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbjQQrlxOCR7" title="Weighted average number of common shares outstanding - basic"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuGNAqz7n9oa" title="Weighted average number of common shares outstanding - diluted">2,676,685</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOIyOdvUXSs4" title="Weighted average number of common shares outstanding - basic"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zS6Ov59S4Oh" title="Weighted average number of common shares outstanding - diluted">494,880</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Weighted-average number of vested RSUs– basic and diluted</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260401__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zY9iF8Bot8r2" title="Weighted average number of vested RSUs - basic"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260401__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zz3tpu2RteN3" title="Weighted average number of vested RSUs - diluted">10,672</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250401__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zuTUmUUaOG96" title="Weighted average number of vested RSUs - basic"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250401__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zLumj7eCPlj6" title="Weighted average number of vested RSUs - diluted">6,981</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zv7mUWYZNW93" title="Weighted average number of vested RSUs - basic"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260101__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zie1zT2JZcUj" title="Weighted average number of vested RSUs - diluted">10,610</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zzqiJeArsOt4" title="Weighted average number of vested RSUs - basic"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zIzitlZZk9tl" title="Weighted average number of vested RSUs - diluted">7,205</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Weighted-average number of common shares-basic and diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"> 2,750,742</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"> 628,796</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">2,687,295</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">502,085</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_89B_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z5DRJXQUN4k2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">We have excluded the following potentially dilutive securities from the calculation of diluted net loss per share since they would have had an anti-dilutive effect: Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="display: none"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20260101__20260630_z6JzRN34J6G7" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2026</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20250101__20250630_zVplusn5AxS1" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zqrqLBRPEeu3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Stock options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">136,372</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">112</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zycZUfmkqbe8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Restricted stock units (unvested)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">45,610</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,056</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zLR4tuqvzrZh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Warrants for common stock</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,430,807</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,219,832</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zlolXlc2g70e" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,612,789</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,222,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

<p id="xdx_89B_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z9x0DbXY5MIb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">The computation of net loss per share for the three and six months ended June 30, 2026 and 2025 was as follows: Schedule of Net Loss Per Share Basic and Diluted <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20260401__20260630_zCtfPyviL7Yd" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20250401__20250630_zmKrGmDlX35d" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20260101__20260630_z1DOP83HvzU" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20250101__20250630_zLB9reV9pvqd" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Basic and diluted net loss per share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zGD1LQZ7vyo5" style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left">Net loss available to common stockholders</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(3,265,494</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(3,933,918</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(6,642,673</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(6,768,323</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Weighted average number of common shares-basic and diluted</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,750,742</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">628,796</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,687,295</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">502,085</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Basic and diluted net loss per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1.19</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(6.26</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2.47</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(13.48</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Weighted-average number of common shares outstanding – basic and diluted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcBuOZbcDn5f" title="Weighted average number of common shares outstanding - basic"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5KsmPJJxy47" title="Weighted average number of common shares outstanding - diluted">2,740,070</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250401__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4dPks3IyWI6" title="Weighted average number of common shares outstanding - basic"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250401__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zN1bxfyZFd0h" title="Weighted average number of common shares outstanding - diluted">621,815</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbjQQrlxOCR7" title="Weighted average number of common shares outstanding - basic"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuGNAqz7n9oa" title="Weighted average number of common shares outstanding - diluted">2,676,685</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOIyOdvUXSs4" title="Weighted average number of common shares outstanding - basic"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zS6Ov59S4Oh" title="Weighted average number of common shares outstanding - diluted">494,880</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Weighted-average number of vested RSUs– basic and diluted</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260401__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zY9iF8Bot8r2" title="Weighted average number of vested RSUs - basic"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260401__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zz3tpu2RteN3" title="Weighted average number of vested RSUs - diluted">10,672</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250401__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zuTUmUUaOG96" title="Weighted average number of vested RSUs - basic"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250401__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zLumj7eCPlj6" title="Weighted average number of vested RSUs - diluted">6,981</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zv7mUWYZNW93" title="Weighted average number of vested RSUs - basic"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260101__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zie1zT2JZcUj" title="Weighted average number of vested RSUs - diluted">10,610</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zzqiJeArsOt4" title="Weighted average number of vested RSUs - basic"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zIzitlZZk9tl" title="Weighted average number of vested RSUs - diluted">7,205</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Weighted-average number of common shares-basic and diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"> 2,750,742</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"> 628,796</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">2,687,295</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">502,085</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

-3265494

-3933918

-6642673

-6768323

2750742

628796

2687295

502085

-1.19

-6.26

-2.47

-13.48

2740070

621815

2676685

494880

10672

6981

10610

7205

2750742

628796

2687295

502085

<p id="xdx_89B_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z5DRJXQUN4k2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">We have excluded the following potentially dilutive securities from the calculation of diluted net loss per share since they would have had an anti-dilutive effect: Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="display: none"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20260101__20260630_z6JzRN34J6G7" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2026</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20250101__20250630_zVplusn5AxS1" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zqrqLBRPEeu3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Stock options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">136,372</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">112</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zycZUfmkqbe8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Restricted stock units (unvested)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">45,610</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,056</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zLR4tuqvzrZh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Warrants for common stock</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,430,807</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,219,832</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zlolXlc2g70e" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,612,789</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,222,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

136372

112

45610

2056

1430807

1219832

1612789

1222000

Note 5 – Digital Assets Digital assets are measured at fair value on a recurring basis using quoted prices in its principal market (Level 1 inputs). We have designated a principal market based on the market we have access to that has the greatest volume and level of orderly transactions for digital assets. We reassess the principal market when facts and circumstances change, including, but not limited to, when new markets become accessible, or the volume/activity in the current principal market declines. The following table sets forth the number of tokens, cost basis and fair value of digital assets held, as shown on the condensed consolidated balance sheet as of June 30, 2026: Schedule of Digital Assets Held <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Tokens</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cost basis</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: justify">CHZ tokens</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--CryptoAssetNumberOfUnits_iI_uCHZ_c20260630__srt--CryptoAssetAxis__custom--CHZDigitalAssetsMember_zuLr50bVq9b" style="width: 14%; text-align: right" title="Tokens">26,517,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--CryptoAssetCost_iI_c20260630__srt--CryptoAssetAxis__custom--CHZDigitalAssetsMember_zJIKcsuJ1oic" style="width: 14%; text-align: right" title="Cost basis">1,004,994</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--CryptoAssetFairValue_iI_c20260630__srt--CryptoAssetAxis__custom--CHZDigitalAssetsMember_zBfBrybkSo43" style="width: 14%; text-align: right" title="Fair value">472,003</td><td style="width: 1%; text-align: left"> </td></tr> </table> The following table represents a reconciliation of our assets and (liabilities) related to our digital assets during the six months ended June 30, 2026: Schedule of Reconciliation of Assets and (Liabilities) Related to Digital Assets <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Six months ended June 30, 2026</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Fair Value, January 1, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--CryptoAssetFairValue_iS_c20260101__20260630_zCx2uc88onAj" style="width: 16%; text-align: right" title="Fair Value, Beginning Balance">1,145,180</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Purchases of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlY29uY2lsaWF0aW9uIG9mIEFzc2V0cyBhbmQgKExpYWJpbGl0aWVzKSBSZWxhdGVkIHRvIERpZ2l0YWwgQXNzZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--CryptoAssetNumberOfUnits_iI_uCHZ_c20260630__srt--CryptoAssetAxis__custom--CHZTokensMember__srt--ProductOrServiceAxis__custom--PurchasedMember_z9kDFjbUjoph" title="Purchase made">10,416,000 CHZ tokens</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--CryptoAssetPurchase_c20260101__20260630_zylr8F1edLRh" style="text-align: right" title="Purchases made">500,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Cash received on sale of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlY29uY2lsaWF0aW9uIG9mIEFzc2V0cyBhbmQgKExpYWJpbGl0aWVzKSBSZWxhdGVkIHRvIERpZ2l0YWwgQXNzZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--CryptoAssetNumberOfUnits_iI_uCHZ_c20260630__srt--CryptoAssetAxis__custom--CHZTokensMember__srt--ProductOrServiceAxis__custom--SoldMember_zRhWHrsOGRob" title="Number of Tokens">11,000,000 CHZ tokens</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ProceedsFromDisposalCryptoAsset_iN_di_c20260101__20260630_zqJx1VwmJgRf" style="text-align: right" title="Cash received from sale of digital asset">(186,000</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Realized loss on sale</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--CryptoAssetRealizedLossOperating_iN_di_c20260101__20260630_zEOIAaC8ZSSd" style="text-align: right" title="Realized loss on sale">(159,005</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Unrealized loss</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--CryptoAssetUnrealizedLossNonoperating_iN_di_c20260101__20260630_zvUzJaLP5srj" style="border-bottom: Black 1pt solid; text-align: right" title="Unrealized loss">(828,172</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Fair Value, June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--CryptoAssetFairValue_iE_c20260101__20260630_zxk9oMYh0Ixl" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair Value, Ending Balance">472,003</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

The following table sets forth the number of tokens, cost basis and fair value of digital assets held, as shown on the condensed consolidated balance sheet as of June 30, 2026: Schedule of Digital Assets Held <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Tokens</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cost basis</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: justify">CHZ tokens</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--CryptoAssetNumberOfUnits_iI_uCHZ_c20260630__srt--CryptoAssetAxis__custom--CHZDigitalAssetsMember_zuLr50bVq9b" style="width: 14%; text-align: right" title="Tokens">26,517,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--CryptoAssetCost_iI_c20260630__srt--CryptoAssetAxis__custom--CHZDigitalAssetsMember_zJIKcsuJ1oic" style="width: 14%; text-align: right" title="Cost basis">1,004,994</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--CryptoAssetFairValue_iI_c20260630__srt--CryptoAssetAxis__custom--CHZDigitalAssetsMember_zBfBrybkSo43" style="width: 14%; text-align: right" title="Fair value">472,003</td><td style="width: 1%; text-align: left"> </td></tr> </table>

26517000

1004994

472003

The following table represents a reconciliation of our assets and (liabilities) related to our digital assets during the six months ended June 30, 2026: Schedule of Reconciliation of Assets and (Liabilities) Related to Digital Assets <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Six months ended June 30, 2026</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Fair Value, January 1, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--CryptoAssetFairValue_iS_c20260101__20260630_zCx2uc88onAj" style="width: 16%; text-align: right" title="Fair Value, Beginning Balance">1,145,180</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Purchases of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlY29uY2lsaWF0aW9uIG9mIEFzc2V0cyBhbmQgKExpYWJpbGl0aWVzKSBSZWxhdGVkIHRvIERpZ2l0YWwgQXNzZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--CryptoAssetNumberOfUnits_iI_uCHZ_c20260630__srt--CryptoAssetAxis__custom--CHZTokensMember__srt--ProductOrServiceAxis__custom--PurchasedMember_z9kDFjbUjoph" title="Purchase made">10,416,000 CHZ tokens</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--CryptoAssetPurchase_c20260101__20260630_zylr8F1edLRh" style="text-align: right" title="Purchases made">500,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Cash received on sale of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlY29uY2lsaWF0aW9uIG9mIEFzc2V0cyBhbmQgKExpYWJpbGl0aWVzKSBSZWxhdGVkIHRvIERpZ2l0YWwgQXNzZXRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--CryptoAssetNumberOfUnits_iI_uCHZ_c20260630__srt--CryptoAssetAxis__custom--CHZTokensMember__srt--ProductOrServiceAxis__custom--SoldMember_zRhWHrsOGRob" title="Number of Tokens">11,000,000 CHZ tokens</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ProceedsFromDisposalCryptoAsset_iN_di_c20260101__20260630_zqJx1VwmJgRf" style="text-align: right" title="Cash received from sale of digital asset">(186,000</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Realized loss on sale</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--CryptoAssetRealizedLossOperating_iN_di_c20260101__20260630_zEOIAaC8ZSSd" style="text-align: right" title="Realized loss on sale">(159,005</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Unrealized loss</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--CryptoAssetUnrealizedLossNonoperating_iN_di_c20260101__20260630_zvUzJaLP5srj" style="border-bottom: Black 1pt solid; text-align: right" title="Unrealized loss">(828,172</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Fair Value, June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--CryptoAssetFairValue_iE_c20260101__20260630_zxk9oMYh0Ixl" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair Value, Ending Balance">472,003</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1145180

10416000

500000

11000000

186000

159005

828172

472003

Note 6 – Related Party Transactions CorLyst, LLC CorLyst, LLC (“CorLyst”) reimburses us for shared costs related to payroll and health insurance (and rent during the three and six months ended June 30, 2025) based on actual costs incurred, which are recognized as a reduction of our general and administrative operating expenses in our condensed consolidated statements of operations. Included in our general and administrative expenses is approximately $<span id="xdx_90A_ecustom--ProceedsFromRentAndOtherCostsReimbursements_c20260401__20260630__us-gaap--RelatedPartyTransactionAxis__custom--CorLystLLCMember_zgf3Xy1QjmD7" title="Rent and other costs reimbursements received">34,000 and $<span id="xdx_901_ecustom--ProceedsFromRentAndOtherCostsReimbursements_c20250401__20250630__us-gaap--RelatedPartyTransactionAxis__custom--CorLystLLCMember_zfhFhIA12N95" title="Rent and other costs reimbursements received">31,000 of reimbursements from CorLyst during the three months ended June 30, 2026 and 2025, respectively, and $<span id="xdx_901_ecustom--ProceedsFromRentAndOtherCostsReimbursements_c20260101__20260630__us-gaap--RelatedPartyTransactionAxis__custom--CorLystLLCMember_z4bfH8c3Elc" title="Rent and other costs reimbursements received">50,000 and $<span id="xdx_905_ecustom--ProceedsFromRentAndOtherCostsReimbursements_c20250101__20250630__us-gaap--RelatedPartyTransactionAxis__custom--CorLystLLCMember_zkNvysHPWvf6" title="Rent and other costs reimbursements received">60,000 for the six months ended June 30, 2026 and 2025, respectively. At June 30, 2025, we included $29,000 due from CorLyst as a current asset in Prepaid and Other. No amounts were due at June 30, 2026. Our President, Research and Development is the CEO of CorLyst, and CorLyst is a stockholder. The Chiliz Group The Chiliz Group (formerly known as ‘HX Entertainment Limited’) is the issuer of the Chiliz Token. In prior periods, they have purchased <span id="xdx_90C_ecustom--NumberOfSharesOwnedByRelatedParty_c20260101__20260630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ChilizGroupMember_z4DF3spgIuc5" title="Number of shares owned by related party">305,644 shares of our common stock for a cumulative $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20260101__20260630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ChilizGroupMember_zjWV7SWpDy1a" title="Net proceeds">1.4 million in net proceeds. At June 30, 2026, the Chiliz Group owned <span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20260630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ChilizGroupMember_zElukOWgaUV7" title="Equity method investment, ownership percentage">10.9% of shares of our common stock outstanding.

34000 31000 50000 60000

29000

305644

1400000

0.109

Note 7 – Segment Reporting We manage our operations as a 1single segment, focused on advancing the clinical-stage BTK inhibitor program and evaluating our legacy pharmaceutical assets. As our chief operating decision maker (CODM), our CEO manages and allocates resources at a consolidated level. He assesses performance, monitors budget versus actual results, and decides how to allocate resources based on net loss that also is reported on the consolidated statement of operations and comprehensive loss as consolidated net loss. <p id="xdx_898_eus-gaap--ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_zBN1Bo8scz1d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">The following table presents reportable segment profit and loss, including significant expense categories, attributable to our reportable segment for the three and six months ended June 30, 2026 and 2025: Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20260401__20260630__us-gaap--StatementBusinessSegmentsAxis__us-gaap--ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_zGd9ROgKEABj" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20250401__20250630__us-gaap--StatementBusinessSegmentsAxis__us-gaap--ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_za6VOH5GllW6" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20260101__20260630__us-gaap--StatementBusinessSegmentsAxis__us-gaap--ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_z7BQ4Z5Ay8Lj" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20250101__20250630__us-gaap--StatementBusinessSegmentsAxis__us-gaap--ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_zwzRmkzh0CU9" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_401_ecustom--PreclinicalClinicalTrialAndOtherCosts_msNILzlEq_zhYaOcGBy5s7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Preclinical, clinical trial and other costs</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">326,117</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">2,142,229</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,749,158</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">3,339,263</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_msNILzlEq_z4QLeRcsmBI2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development personnel expense(1)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">323,760</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">305,057</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">709,883</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">696,504</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--OtherGeneralAndAdministrativeExpense_msNILzlEq_zxFaxvbHPeh2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">General and administrative personnel expense(2)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">585,743</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">628,330</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,262,170</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,302,167</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--AdministrativeAndFacilitiesExpense_msNILzlEq_zWKi1LSCGFL" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Administrative and facilities expense(3)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,100,518</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">875,167</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,946,141</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,459,839</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--OtherNonoperatingIncomeExpense_iN_di_maNILzlEq_z5HRrQvjs2Xe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Other expense, net(4)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">929,356</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(16,865</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">975,321</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(29,450</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--NetIncomeLoss_iNT_di_mtNILzlEq_zbZdEdfeHGDj" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,265,494</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,933,918</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,642,673</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,768,323</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--NetIncomeLoss_iNT_di_mtNILzlEq_zV89qNfEYYy1" style="display: none; vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Net Loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,265,494</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,933,918</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,642,673</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,768,323</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: right">(1)</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Research and development personnel costs include employee stock-based compensation expense of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_c20260401__20260630__us-gaap--NatureOfExpenseAxis__custom--ResearchAndDevelopmentPersonnelCostsMember_ztgpWDFuwYWh" title="Personnel costs include employee stock-based compensation expense">17,145 and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_c20250401__20250630__us-gaap--NatureOfExpenseAxis__custom--ResearchAndDevelopmentPersonnelCostsMember_zhARY08JbHnk" title="Personnel costs include employee stock-based compensation expense">8,613 for the three months ended June 30, 2026 and 2025, respectively, and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--AllocatedShareBasedCompensationExpense_c20260101__20260630__us-gaap--NatureOfExpenseAxis__custom--ResearchAndDevelopmentPersonnelCostsMember_zlE021MJaiO" title="Personnel costs include employee stock-based compensation expense">34,289 and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--AllocatedShareBasedCompensationExpense_c20250101__20250630__us-gaap--NatureOfExpenseAxis__custom--ResearchAndDevelopmentPersonnelCostsMember_zrLSqCtLnEV4" title="Personnel costs include employee stock-based compensation expense">55,333 for the six months ended June 30, 2026 and 2025, respectively.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(2)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">General and administrative personnel costs include employee stock-based compensation expense of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_c20260401__20260630__us-gaap--NatureOfExpenseAxis__custom--GeneralAndAdministrativePersonnelCostsMember_zndVeQyZbYx1" title="Personnel costs include employee stock-based compensation expense">48,528 and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--AllocatedShareBasedCompensationExpense_c20250401__20250630__us-gaap--NatureOfExpenseAxis__custom--GeneralAndAdministrativePersonnelCostsMember_zaRTuxmhXRu" title="Personnel costs include employee stock-based compensation expense">122,655 for the three months ended June 30, 2026 and 2025, respectively, and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_c20260101__20260630__us-gaap--NatureOfExpenseAxis__custom--GeneralAndAdministrativePersonnelCostsMember_zwHxdPZv1tQ1" title="Personnel costs include employee stock-based compensation expense">100,915 and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20250101__20250630__us-gaap--NatureOfExpenseAxis__custom--GeneralAndAdministrativePersonnelCostsMember_zxTvNeYWTunj" title="Personnel costs include employee stock-based compensation expense">245,310 for the six months ended June 30, 2026 and 2025, respectively, and are net of reimbursements received from CorLyst, LLC.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(3)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Administrative & facilities expense primarily consists of facilities expenses, office expenses, legal costs, insurance, consulting, travel, and other administrative costs.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(4)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Other income, net consists of interest and dividend income, realized and unrealized loss on our digital asset, and other miscellaneous income.</td></tr> </table>

<p id="xdx_898_eus-gaap--ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_zBN1Bo8scz1d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">The following table presents reportable segment profit and loss, including significant expense categories, attributable to our reportable segment for the three and six months ended June 30, 2026 and 2025: Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20260401__20260630__us-gaap--StatementBusinessSegmentsAxis__us-gaap--ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_zGd9ROgKEABj" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20250401__20250630__us-gaap--StatementBusinessSegmentsAxis__us-gaap--ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_za6VOH5GllW6" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20260101__20260630__us-gaap--StatementBusinessSegmentsAxis__us-gaap--ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_z7BQ4Z5Ay8Lj" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20250101__20250630__us-gaap--StatementBusinessSegmentsAxis__us-gaap--ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_zwzRmkzh0CU9" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_401_ecustom--PreclinicalClinicalTrialAndOtherCosts_msNILzlEq_zhYaOcGBy5s7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Preclinical, clinical trial and other costs</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">326,117</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">2,142,229</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,749,158</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">3,339,263</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_msNILzlEq_z4QLeRcsmBI2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development personnel expense(1)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">323,760</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">305,057</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">709,883</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">696,504</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--OtherGeneralAndAdministrativeExpense_msNILzlEq_zxFaxvbHPeh2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">General and administrative personnel expense(2)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">585,743</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">628,330</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,262,170</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,302,167</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--AdministrativeAndFacilitiesExpense_msNILzlEq_zWKi1LSCGFL" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Administrative and facilities expense(3)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,100,518</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">875,167</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,946,141</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,459,839</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--OtherNonoperatingIncomeExpense_iN_di_maNILzlEq_z5HRrQvjs2Xe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Other expense, net(4)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">929,356</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(16,865</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">975,321</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(29,450</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--NetIncomeLoss_iNT_di_mtNILzlEq_zbZdEdfeHGDj" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,265,494</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,933,918</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,642,673</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,768,323</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--NetIncomeLoss_iNT_di_mtNILzlEq_zV89qNfEYYy1" style="display: none; vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Net Loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,265,494</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,933,918</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,642,673</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,768,323</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: right">(1)</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Research and development personnel costs include employee stock-based compensation expense of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_c20260401__20260630__us-gaap--NatureOfExpenseAxis__custom--ResearchAndDevelopmentPersonnelCostsMember_ztgpWDFuwYWh" title="Personnel costs include employee stock-based compensation expense">17,145 and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_c20250401__20250630__us-gaap--NatureOfExpenseAxis__custom--ResearchAndDevelopmentPersonnelCostsMember_zhARY08JbHnk" title="Personnel costs include employee stock-based compensation expense">8,613 for the three months ended June 30, 2026 and 2025, respectively, and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--AllocatedShareBasedCompensationExpense_c20260101__20260630__us-gaap--NatureOfExpenseAxis__custom--ResearchAndDevelopmentPersonnelCostsMember_zlE021MJaiO" title="Personnel costs include employee stock-based compensation expense">34,289 and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--AllocatedShareBasedCompensationExpense_c20250101__20250630__us-gaap--NatureOfExpenseAxis__custom--ResearchAndDevelopmentPersonnelCostsMember_zrLSqCtLnEV4" title="Personnel costs include employee stock-based compensation expense">55,333 for the six months ended June 30, 2026 and 2025, respectively.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(2)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">General and administrative personnel costs include employee stock-based compensation expense of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_c20260401__20260630__us-gaap--NatureOfExpenseAxis__custom--GeneralAndAdministrativePersonnelCostsMember_zndVeQyZbYx1" title="Personnel costs include employee stock-based compensation expense">48,528 and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--AllocatedShareBasedCompensationExpense_c20250401__20250630__us-gaap--NatureOfExpenseAxis__custom--GeneralAndAdministrativePersonnelCostsMember_zaRTuxmhXRu" title="Personnel costs include employee stock-based compensation expense">122,655 for the three months ended June 30, 2026 and 2025, respectively, and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_c20260101__20260630__us-gaap--NatureOfExpenseAxis__custom--GeneralAndAdministrativePersonnelCostsMember_zwHxdPZv1tQ1" title="Personnel costs include employee stock-based compensation expense">100,915 and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlcG9ydGFibGUgU2VnbWVudCBQcm9maXQgYW5kIExvc3MsIEluY2x1ZGluZyBTaWduaWZpY2FudCBFeHBlbnNlIENhdGVnb3JpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20250101__20250630__us-gaap--NatureOfExpenseAxis__custom--GeneralAndAdministrativePersonnelCostsMember_zxTvNeYWTunj" title="Personnel costs include employee stock-based compensation expense">245,310 for the six months ended June 30, 2026 and 2025, respectively, and are net of reimbursements received from CorLyst, LLC.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(3)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Administrative & facilities expense primarily consists of facilities expenses, office expenses, legal costs, insurance, consulting, travel, and other administrative costs.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(4)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Other income, net consists of interest and dividend income, realized and unrealized loss on our digital asset, and other miscellaneous income.</td></tr> </table>

326117 2142229 1749158 3339263

323760

305057

709883

696504

585743

628330

1262170

1302167

1100518 875167 1946141 1459839

-929356

16865

-975321

29450

-3265494

-3933918

-6642673

-6768323

-3265494

-3933918

-6642673

-6768323

17145

8613

34289

55333

48528

122655

100915

245310

Note 8 – Commitments and Contingencies Purchase Obligations We enter into contracts in the normal course of business with contract research organizations (CROs) and subcontractors to further develop our products. The contracts are cancelable, with varying provisions regarding termination. If we terminated a cancelable contract with a specific vendor, we would only be obligated for products or services that we received at the effective date of the termination and any applicable cancellation fees. At June 30, 2026, we are contractually obligated to pay up to $<span id="xdx_90C_eus-gaap--PurchaseObligation_iI_pn5n6_c20260630__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--AgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ContractResearchOrganizationMember_zrJTvQ2ghM36" title="Purchase obligations">10.3 million of future services under the agreements with the CROs. However, following the termination of our license agreement with Elion (see Note 9), we will be closing our ongoing NGC-Cap (also known as PCS6422 + Capecitabine) Phase 2 trial and expect the costs to wind down the trial to be $1 million over the next six months. Actual costs to wind down the trial could exceed these estimates.

10300000

1000000

Note 9 – Subsequent Events Acquisition of Vidya Therapeutics, Inc. and Concurrent Private Placement On July 28, 2026, we acquired Vidya pursuant to the Merger Agreement. Under the terms of the Merger Agreement, we issued to the stockholders of Vidya an aggregate of (i) <span id="xdx_902_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c20260728__20260728__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--BusinessAcquisitionAxis__custom--VidyaTherapeuticsIncMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_zOeeMS6U30C8" title="Shares issued on consideration">558,398 shares of our common stock issuable upon exercise of the Vidya Assumed Options (as defined below) and (ii) <span id="xdx_90A_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_pp3d_c20260728__20260728__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--BusinessAcquisitionAxis__custom--VidyaTherapeuticsIncMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zj11fTm6QJG5" title="Shares issued on consideration">142,744.100 shares of Series A Preferred Stock (or <span id="xdx_907_ecustom--CommonStockSharesIssuableUponConversionOfConvertiblePreferredStock_pid_c20260728__20260728__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--BusinessAcquisitionAxis__custom--VidyaTherapeuticsIncMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_zEeWP1FmwjOi" title="Conversion of shares">142,744,100 shares of our common stock on an as-converted basis and without giving effect to any beneficial ownership limitations). The powers, preferences, rights, qualifications, limitations and restrictions applicable to the Series A Preferred Stock are set forth in the Certificate of Designation. Further, pursuant to the terms of the Merger Agreement, each option to purchase Vidya common stock was assumed by us (the “Vidya Assumed Options”) and converted into an option to purchase our common stock, which options are subject to exercise restrictions prior to obtaining the approval of the Stockholder Matters. Concurrently with the Vidya Acquisition, on July 28, 2026, we entered into a Securities Purchase Agreement (the “Purchase Agreement”) for a $<span id="xdx_908_ecustom--GrossProceedsFromIssuanceOfPrivatePlacement_pn6n6_c20260730__20260730__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zs3gJYpCXbAg" title="Gross proceeds from issuance of private placement">200 million private placement financing, pursuant to which we agreed to sell an aggregate of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp3d_c20260730__20260730__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zG9yJCRH4RKb" title="Stock issued during period shares new issues">163,774.679 shares of Series A Preferred Stock (or <span id="xdx_90B_ecustom--CommonStockSharesIssuableUponConversionOfConvertiblePreferredStock_pid_c20260730__20260730__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zablCVbjCw26" title="Common shares issuable upon conversion of preferred stock">163,774,679 shares of our common stock on an as-converted basis and without giving effect to any beneficial ownership limitations) at a price of $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_c20260730__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zTjHGcYymwGe" title="Share issued price per shares">1,221.19 per share (or $<span id="xdx_908_ecustom--ConversionPricePerShare_iI_c20260730__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zIEuEresowck" title="Conversion price per share">1.22119 per share on an as-converted basis) (collectively, the “2026 Private Placement”). The 2026 Private Placement closed on July 30, 2026. Pursuant to the Merger Agreement and the Purchase Agreement we agreed to hold a stockholders’ meeting to submit certain matters to our stockholders for their consideration including: (i) the approval in accordance with applicable rules of the Nasdaq Stock Market, LLC (the “Nasdaq”) of the conversion of the Series A Preferred Stock issued pursuant to the Merger Agreement and the Purchase Agreement into shares of our common stock (the “Preferred Stock Conversion Proposal”), (ii) the approval of a 2026 Equity Incentive Plan, subject to approval by the Board, (iii) the approval of a 2026 Employee Stock Purchase Plan, and (iv) to the extent deemed necessary or advisable by the Company and/or Vidya, approval of an amendment to the Company’s certificate of incorporation to effect a reverse stock split (the matters contemplated in items (i) through (iv) collectively, the “Stockholder Matters”). Subject to the receipt of stockholder approval of the Stockholder Matters, each share of Series A Preferred Stock will automatically convert into <span id="xdx_90F_eus-gaap--ConversionOfStockSharesConverted1_c20260728__20260728__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--BusinessAcquisitionAxis__custom--VidyaTherapeuticsIncMember_zNJxWZU04SWg" title="Conversion of shares">1,000 shares of Common Stock, subject to certain beneficial ownership limitations established by each holder. <span id="xdx_90C_eus-gaap--BusinessAcquisitionEquityInterestIssuedOrIssuableDescription_c20260728__20260728__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--BusinessAcquisitionAxis__custom--VidyaTherapeuticsIncMember_z1iXOc7k3VFi" title="Description for equity interest">As a result of the acquisition and private placement transactions, our equity holders immediately prior to the Vidya Acquisition owned approximately 1.0% of our common stock, equity holders of Vidya immediately prior to the Vidya Acquisition owned approximately 46.0% of our common stock and investors in the 2026 Private Placement owned approximately 53.0% of our common stock, in each case, calculated on a fully-diluted basis (without giving effect to any beneficial ownership limitations and assuming the conversion in full of the Series A Preferred Stock) and based on our and Vidya’s implied equity values. Amendments to our Articles of Incorporation - Series A Non-Voting Convertible Preferred Stock In connection with the Merger Agreement, on July 28, 2026, we filed a Certificate of Designation of Preferences, Rights and Limitations of the Series A Preferred Stock with the Secretary of State of the State of Delaware , as adopted by the Board. The Certificate of Designation provided for the creation of our Series A Preferred Stock. Holders of Series A Preferred Stock are entitled to receive dividends on shares of Series A Preferred Stock equal to, on an as-if-converted-to-Common-Stock basis, and in the same form as dividends actually paid on shares of our common stock. Except as otherwise provided in the Certificate of Designation or as otherwise required by the General Corporation Law of the State of Delaware, the Series A Preferred Stock shall have no voting rights. However, as long as any shares of Series A Preferred Stock are outstanding, we shall not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series A Preferred Stock: (i) alter or change adversely the powers, preferences or rights given to the Series A Preferred Stock or alter or amend the Certificate of Designation, amend its certificate of incorporation or other charter documents in any manner that adversely affects any rights of the holders of Series A Preferred Stock, (ii) issue additional shares of Series A Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of Series A Preferred Stock, (iii) prior to the Automatic Conversion, consummate either: (A) any Fundamental Transaction (as defined in the Certificate of Designation) or (B) any merger or consolidation with or into another Person or any stock sale to, or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, share exchange or scheme of arrangement) with or into, another Person in which our shareholders immediately before such transaction do not hold at least a majority of the voting power of our capital stock or surviving corporation or the parent entity of ours or surviving corporation immediately after such transaction or in which we or the surviving corporation issues securities in such transaction that represent, or are convertible into securities representing, more than a majority of the voting power of the Company immediately before such transaction, (iv) prior to the stockholder approval of the Preferred Stock Conversion Proposal, authorize or issue any class or series of stock that has powers, preferences or rights that are senior to those of the Series A Preferred Stock, (v) amend, waive or modify the Merger Agreement in any manner that would be reasonably likely to prevent, impede or materially delay stockholder approval of the Preferred Stock Conversion Proposal or the Automatic Conversion (as defined below) or (vi) enter into any agreement with respect to any of the foregoing. At 5:00 pm Eastern time on the third business day following stockholder approval of the Preferred Stock Conversion Proposal, each share of Series A Preferred Stock will automatically convert into <span id="xdx_907_eus-gaap--ConversionOfStockSharesConverted1_c20260728__20260728__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zcWwdlBwdtra" title="Conversion of shares">1,000 shares of our common stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.9% and 19.9%) of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion; provided that following stockholder approval of the Preferred Stock Conversion Proposal, such Beneficial Ownership Limitation may be waived by each holder of Series A Preferred Stock upon written notice to the Company to be effective on the 61st day following receipt of such notice. If at any time after the earlier of (i) the Stockholder Approval or (ii) nine months after the initial issuance of the Series A Preferred Stock, the Company fails to deliver to the holder of the Series A Preferred Stock shares of Common Stock underlying such shares of Series A Preferred Stock, then (other than in certain circumstances set forth in the Certificate of Designation), the Company will pay, at the request of such holder, an amount of cash by wire transfer of immediately available funds equal to the Fair Value (as defined in the Certificate of Designation) of such undelivered shares, provided that the Company has funds legally available for such payment. Appointment of Dr. Gujrathi to our Board of Directors In accordance with the Merger Agreement, on July 28, 2026, Dr. Sheila Gujrathi was appointed to the Board as a director. Amendment of our License Agreement with Yuhan Corporation On August 14, 2026, Yuhan Corporation executed Amendment No. 2 to our existing license agreement dated August 19, 2020 (the “Yuhan Agreement”), effective August 14, 2026, which, extended the deadline to dose the first patient in a Phase 2B clinical trial, Phase 3 clinical trial or other pivotal clinical trial by August 14, 2027. Termination of our License Agreement with Elion Oncology, Inc. On July 23, 2026, we terminated our License Agreement, dated August 23, 2020 with Elion Oncology, Inc. (“Elion”). Pursuant to the Settlement, the parties agreed to settle all claims in respect of our litigation regarding the Elion License Agreement and to terminate the Elion License Agreement without further obligation of either party, with us returning the PCS6422 program to Elion. In connection with the Settlement, the parties exchanged mutual releases of all claims relating to the Elion License Agreement, the PCS6422 program and the related litigation. As part of the Settlement, we agreed to pay Elion the sum of $650,000 towards Elion’s attorneys’ fees and/or other out-of-pocket costs. <span id="xdx_906_ecustom--DescriptionForTerminationOfLicenseAgreement_c20260723__20260723__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zKVWEEtvO1Nh" title="Description for termination of license Agreement">In addition, we agreed to grant to Elion a non-voting equity interest equal to seven and one-half percent (7.5%) of the fully diluted pre-money equity capitalization of any newly formed entity whose assets include one or more of PCS499, PCS12852, and/or PCS11T, if the formation or spin-out is completed within three hundred sixty-five (365) days following the effective date of the Settlement Agreement. On August 7, 2026, the filed stipulation became effective as a final dismissal with prejudice. Accordingly, we will be closing our ongoing Phase 2 trial of PCS6422 in advanced/metastatic breast cancer.

558398

142744.100

142744100 200000000

163774.679

163774679

1221.19

1.22119

1000

As a result of the acquisition and private placement transactions, our equity holders immediately prior to the Vidya Acquisition owned approximately 1.0% of our common stock, equity holders of Vidya immediately prior to the Vidya Acquisition owned approximately 46.0% of our common stock and investors in the 2026 Private Placement owned approximately 53.0% of our common stock, in each case, calculated on a fully-diluted basis (without giving effect to any beneficial ownership limitations and assuming the conversion in full of the Series A Preferred Stock) and based on our and Vidya’s implied equity values.

1000

650000

In addition, we agreed to grant to Elion a non-voting equity interest equal to seven and one-half percent (7.5%) of the fully diluted pre-money equity capitalization of any newly formed entity whose assets include one or more of PCS499, PCS12852, and/or PCS11T, if the formation or spin-out is completed within three hundred sixty-five (365) days following the effective date of the Settlement Agreement. On August 7, 2026, the filed stipulation became effective as a final dismissal with prejudice. false false false false Research and development personnel costs include employee stock-based compensation expense of $17,145 and $8,613 for the three months ended June 30, 2026 and 2025, respectively, and $34,289 and $55,333 for the six months ended June 30, 2026 and 2025, respectively. General and administrative personnel costs include employee stock-based compensation expense of $48,528 and $122,655 for the three months ended June 30, 2026 and 2025, respectively, and $100,915 and $245,310 for the six months ended June 30, 2026 and 2025, respectively, and are net of reimbursements received from CorLyst, LLC. Administrative & facilities expense primarily consists of facilities expenses, office expenses, legal costs, insurance, consulting, travel, and other administrative costs. Other income, net consists of interest and dividend income, realized and unrealized loss on our digital asset, and other miscellaneous income.